MEDICATION RECALL: IMPORTANT NOTICE – OA/RA capsules
OA/RA capsules: Recall due to contamination23 January 2019
Consumers and health professionals are advised that Blueskygreenearth, in consultation with the TGA, is recalling OA/RA capsules (batch 17098003) due to contamination with a substance that poses an unacceptable risk to health. This product has also been withdrawn from the Australian market and will no longer be available for supply.
OA/RA is an Ayurvedic product that is indicated for temporary pain relief of osteoarthritis (OA) and rheumatoid arthritis (RA).
TGA testing has found that the currently available batch of the product is contaminated with very low levels of aristolochic acid.
Aristolochic acid is included in Schedule 10 to the Poisons Standard, which lists substances considered to pose an unacceptable risk to health. There is no established safe exposure level to aristolochic acids, which have been linked to kidney problems and urinary tract cancers.
Information for consumers
If you or someone you provide care for takes OA/RA capsules, please be alert to this issue and discontinue use immediately.
The product should not be consumed.
If you have any OA/RA capsules, the remaining product can be returned to the place of purchase for a refund.
If you have any questions or concerns about this issue, talk to your health professional or contact 1300 133 807.
Information for health professionals
Please be aware of the above issue and advise patients regarding alternative treatment options if they seek advice.If you have any questions or concerns about this issue, contact 1300 133 807.
Consumers and health professionals are encouraged to report problems with medicines or vaccines. Your report will contribute to the TGA’s monitoring of these products.
The TGA cannot give advice about an individual’s medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine or vaccine.
$120,000 scholarship to combat ‘serious shortage’ of paediatric rheumatologists in Australia so kids with arthritis get the care they need
On offer is a two-year scholarship to support paediatricians and paediatric trainees interested in training in paediatric rheumatology. The scholarship will be equivalent to the...
Musculoskeletal conditions, including arthritis, now the most costly disease group in Australia
The health system cost of musculoskeletal conditions, including arthritis, was $12.5 billion in 2015-16, up from $5.7 billion in 2008-09. The cost of these conditions...
Online resource to help sufferers ease back pain
A comprehensive tool to help people manage back pain has been developed by a team of international health experts led by University of Queensland researchers....
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox: